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Immune modulationIn the present study, circulating proportions of CD8+ T (Tc) cell subsets, including IL-17 (Tc17) and IL-10
(Tc10) producing cells, were assessed in relapsing–remitting MS (RRMS) patients and a possible effect of
beta interferon (IFN-β), glatiramer acetate (GA), and vitamin D (VitD) on these cell subsets was investigated.
We show that both Tc17 and Tc10 cell fractions are elevated in the circulation of RRMS patients in remission
compared to healthy subjects and that these Tc subsets remain unaffected by current immune modulating
regimens.
© 2013 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Multiple sclerosis (MS) is considered to be a T cell mediated
autoimmune disease. Although research focused mainly on CD4+ T
helper (Th) cells, CD8+ cytotoxic T (Tc) cells may be importantly
involved in MS pathogenesis as well. It was demonstrated that adop-
tively transferred myelin speciﬁc Tc cells could induce experimental
autoimmune encephalomyelitis (EAE) (Huseby et al., 2001; Sun
et al., 2001), the animal model for MS. Certain MHC class I alleles
were identiﬁed as MS disease risk alleles (reviewed by Martin,
2008) and MHC class I expression was higher on astrocytes and
oligodendrocytes in MS lesions compared to normal brain tissue
(Hoftberger et al., 2004). Tc cells could be detected in MS brain
lesions and they even outnumbered Th cells. These Tc cells were
found in the vicinity of damaged oligodendrocytes and myelin
containing antigen presenting cells (Neumann et al., 2002; Seraﬁni
et al., 2006). In addition, the intralesional Tc cells, as well as Tc cells
in the cerebrospinal ﬂuid (CSF), are clonally expanded, suggesting
antigen speciﬁc reactivity (Babbe et al., 2000; Jacobsen et al., 2002).and Neuroscience, Maastricht
5.302, PO Box 616, 6200 MD
.nl (E. Peelen).
evier OA license.Together, these data suggest active involvement of Tc cells in MS
pathogenesis.
Like Th cells, Tc cells can be divided into different subsets based on
their cytokine proﬁle. In MS patients, research focused mainly on
peripheral IFN-γ+ and IL-4+ Tc cells (Tc1 and Tc2, respectively).
Studies regarding the Tc1 cell percentages show contradictory results,
whereas studies regarding the Tc2 cell fractions show no difference
between MS patients and healthy controls (Becher et al., 1999;
Inoges et al., 1999; Furlan et al., 2000; Killestein et al., 2001; Ochi
et al., 2001; Sepulcre et al., 2005). Recently, an IL-17 producing cell
subset within the Tc cell compartment (Tc17) was identiﬁed. Interest-
ingly, Wang et al. showed that Tc17 cells are increased in the peripheral
blood of relapsing–remitting MS patients (RRMS) (Wang et al., 2011)
and more than 70% of the Tc cells in MS brain tissue are IL-17 positive
(Tzartos et al., 2008). Next to Tc17 cells, IL-10 producing Tc (Tc10)
cells have been described as cells important in tissue protection during
a viral infection (reviewed by Zhang and Bevan, 2011). These cells
might also be importantly involved in controlling inﬂammation in MS
patients.
In this study, we investigated the Tc cell compartment, including
Tc17 and Tc10 cells, in healthy volunteers and RRMS patients in
remission and during a relapse. We measured fractions of Tc cell
subsets and investigated the effects of ﬁrst line immune modulating
treatments for RRMS, i.e. beta interferon (IFN-β) and glatiramer
acetate (GA). Moreover, we examined the effect of high dose vitamin
78 E. Peelen et al. / Journal of Neuroimmunology 258 (2013) 77–84D supplementation, as add-on therapy to IFN-β, on Tc10 and Tc17 cell
fractions.2. Methods
2.1. Patients and blood sampling
In total, 73 RRMS patients were included in this study. Sixty-four
RRMS patients were enrolled from the Academic MS Center at Orbis
Medical Center (Sittard, The Netherlands), and 9 RRMS patients
were enrolled from the MS Center at Amphia Hospital (Breda,
The Netherlands). RRMS was deﬁned by the revised McDonald
criteria (Polman et al., 2011). Only RRMS patients with a disease
duration b 6 years were included and RRMS patients in remission
had to be relapse free for at least 6 weeks. Written informed consent
was obtained from each study subject and the study was approved by
the regional ethical committee ‘Atrium-Orbis-Zuyd’, ‘Local Advisory
Board on Scientiﬁc Research’ of Orbis Medical Center and ‘the medical
ethical committee of Amphia’ of Amphia Hospital.
Tc cell fractions in HC and MS patients in remission or during a
relapse and the effects of IFN-β and GA were studied in a cross-
sectional cohort study in which 59 RRMS patients and 30 HC were
enrolled. Gender and age of the MS patients matched that of the HC.
Characteristics of these populations are given in Table 1. Forty-seven
MS patients were in disease remission and were either using no
immune modulatory drugs (n = 16), or were treated with IFN-β 1a/1b
(n = 18) or GA (n = 13). Twelve RRMS patients were included while
having a relapse. None of these patients were on immune modulating
therapy. A relapse was deﬁned as occurrence of new symptoms which
lasted at least 24 h and required treatment with intravenous methyl-
prednisolone. Blood samples were retrieved before methylprednisolone
infusion.
The association of vitamin D with different Tc cell subsets
was studied in the above described cross-sectional cohort and the
inﬂuence of vitamin D supplementation on the composition of the Tc
cell compartment was studied in 14 RRMS patients who received a
daily dose of 20,000 IU vitamin D3 for 12 weeks. All 14 supplemented
patients were in remission and were treated with IFN-β 1a/1b.
Blood samples for T cell phenotyping were retrieved at baseline and
at 12 weeks. Detailed population characteristics are described by
Smolders et al. (2010b).2.2. Serum 25(OH)D assessment
Serum samples were stored directly after sampling until analysis
at -20 °C. A radioimmunoassay kit (Immunodiagnostic Systems,
Boldon, UK) was used to determine serum 25-hydroxyvitamin D
(25(OH)D) levels (representing the vitamin D status).Table 1




Number of subjects 30 16
Gender: Male 8 (26.7) 2 (12.5)
Female 22 (73.3) 14 (87.5)
Age (y) 41.0 [30.8–47.3] 38.4 [29.0–46.8]
Disease duration (y) – 2.6 [0.7–4.1]
Relapse rate (relapse/y) – 1.0 [0.0–1.0]
Time since last relapse (y) – 0.8 [0.2–1.0]
EDSS score – 1.5 [1.0–2.5]
HC = healthy controls;MS = multiple sclerosis; EDSS = expandeddisability status scale; IQR =2.3. Intracellular ﬂow cytometry
Ficoll density gradient centrifugation (Histopaque; Sigma Aldrich,
Zwijndrecht, The Netherlands) was used to isolate peripheral blood
mononuclear cells (PBMC). To assess the intracellular CD8+ T cell cyto-
kine proﬁle, PBMC were stimulated with 1 μg/mL calcium ionomycine
(Sigma Aldrich) and 50 ng/mL PMA (Sigma Aldrich) for 5 h. Monensin
(BD Biosciences, Breda, The Netherlands) was added simultaneously to
block cytokine secretion. After stimulation, cells were stained extra-
cellularly with anti-CD3-horizon V450 and anti-CD8-APC-H7 (both
BD Biosciences). Next, the cells were ﬁxed and permeabilized using
ﬁxation/permeabilization buffer (BD Biosciences). Cells were then
stained intracellularly with anti-IFN-γ-FITC (BD Biosciences), anti-IL-4-
PE, anti-IL-10-APC and anti-IL-17A-PerCP-Cy5.5 (all Biolegend, Uithoorn,
The Netherlands). Samples were acquired on a FACS Canto II ﬂow
cytometer (BD Biosciences) and data analysis was performed using the
FACS Diva software (BD Biosciences). On average 10,000 events within
the CD8+ T cell gate were acquired. A representative example of our
gating strategy and speciﬁcity of the staining is illustrated in Fig. 1.
2.4. Statistics
Statistical analysis was performed with Statistical Package for
Social Sciences version 17.0 software (SPSS Inc., Chicago, IL). Continuous
data are given as median with corresponding interquartile range (IQR).
Differences in continuous variables between groups were tested using
the Mann–Whitney U test. Associations between the vitamin D status
and the different cytokine producing CD8+ T cells were assessed with
the Spearman correlation. Paired variables were analyzed with the
Wilcoxon Signed Ranks test. A p-value b0.05was considered statistically
signiﬁcant.
3. Results
3.1. The fraction cytokine producing CD8+ T cell subsets in RRMS patients
First, we assessed the percentages of IFN-γ+, IL-4+, IL-10+ and
IL-17+ cells within the CD8+ T cell population (Tc1, Tc2, Tc10 and
Tc17, respectively) in HC, in untreated RRMS patients in remission,
and in untreated RRMS patients during a relapse. The fraction
Tc1 cells (Fig. 2A) was similar between HC (24.2% [16.9–35.0]) and
untreated RRMS patients in remission (34.2% [14.8–42.2]) and between
untreated RRMS patients in remission and during a relapse (23.8%
[17.6–34.8]). In addition, Tc2 cell percentages (Fig. 2B) did not differ
between untreated RRMS patients in remission (1.6% [0.8–2.9]) and
HC (1.2% [0.8–1.6]), or untreated RRMS patients during a relapse (1.1%
[0.7–1.3]). Interestingly, the median Tc10 cell percentage (Fig. 2C)
was higher in untreated RRMS patients in remission (0.5% [0.2–0.5])
compared to HC (0.2% [0.2–0.3], p = 0.011), while there was noMS relapse
IFN-β GA No
18 13 12
4 (22.2) 1 (7.7) 3 (25.0)
14 (77.8) 12 (92.3) 9 (75.0)
43.0 [32.5–51.0] 39.5 [33.7–46.2] 32.0 [28.3–38.0]
3.6 [1.9–4.4] 1.2 [0.1–2.1] 2.7 [0.4–3.9]
0.0 [0.0–0.3] 0.0 [0.0–1.0] 1.0 [0.0–1.0]
2.5 [0.6–4.4] 0.9 [0.4–1.2] 1.0 [0.4–2.2]
1.5 [1.0–3.3] 1.5 [1.0–1.5] 2.0 [1.3–2.5]
interquartile range; IFN-β = beta interferon; GA = glatiramer acetate; No = no treatment.
Fig. 1. Representative gating strategy for Tc10 and Tc17 cells. A representative gating strategy is depicted starting at the lymphocyte gate. Within this gate singlets were selected.
From the singlet gate, the fraction CD8 CD3 positive cells were determined. Within the CD8 T cell gate we investigated the IL-10 and IL-17 positive cells. The speciﬁc staining for
IL-10 and IL-17 as well as their isotype controls are shown.
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relapse (0.4% [0.2–0.8]). Also, the percentage Tc17 cells (Fig. 2D)
was higher in RRMS patients in remission (0.5% [0.3–0.7]) compared
to HC (0.3% [0.2–0.4], p = 0.003). Again, there was no difference
between untreated RRMS patients in remission and during a relapse
(0.4% [0.2–1.4]).
Next to the total Tc10 and Tc17 cell subsets, double producing Tc cell
subsets, e.g. IL-10+IL-17+, IFN-γ+IL-17+ and IFN-γ+IL-10+ Tc cells,
might be of interest. IL-10+IL-17+ Tc cell percentages are hardly detect-
able (Fig. 1) and overall numbers were too low for reliable analysis
(data not shown). The IFN-γ+IL-17+ and IFN-γ+IL-10+ Tc cell
percentages are increased in untreated RRMS patients in remission
(0.21% [0.11–0.32] and 0.20% [0.10–0.25], respectively) compared to
HC (0.12% [0.08–0.15]; p = 0.017 and 0.08% [0.05–0.11]; p = 0.002,
respectively), while these percentages were similar compared
to untreated RRMS patient during a relapse (0.18% [0.06–0.51];
p = 0.728 and 0.16% [0.07–0.34]; p = 0.944, respectively; Fig. 2E–F).
Since the percentage IFN-γ+ cells within both Tc10 and Tc17 cellsubsets was on average 40%, the changes observed in the IFN-
γ+IL-10+ and IFN-γ+IL-17+ Tc cell percentages might just parallel
with the changes in the fraction of Tc10 and Tc17 cells, respectively.3.2. Treatment effects on the fraction cytokine producing CD8+ T
cell subsets
Next, we assessed if RRMS patients in remission on IFN-β or GA
treatment differed in the relative presence of cytokine producing
CD8+ T cell subsets as compared to untreated RRMS patients in
remission. Compared to untreated RRMS patients (34.2% [14.8–42.2]),
Tc1 cell percentages (Fig. 3A) are lower in patients on IFN-β (12.4%
[8.9–23.1], p = 0.011), but not in patients on GA treatment (30.1%
[14.0–42.1]). Tc2, Tc10 and Tc17 cell percentages did not differ between
the treatment groups and the untreated RRMS patients (Fig. 3B–D).
In addition, IFN-γ+IL-10+ and IFN-γ+IL-17+ Tc cell frequencies were
similar between the different treatment cohorts (data not shown).
Fig. 2. The percentage cytokine producing CD8+ T cell subsets in MS patients. The percentage of IFN-γ+ (A), IL-4+ (B), IL-10+ (C), IL-17+ (D), IFN-γ+IL-17+ (E) and IFN-γ+IL-10+
(F) cells within CD8+ T cells from healthy controls (HC, n = 30), MS patients in remission (n = 16) and MS patients during a relapse (n = 12). Black horizontal lines indicate the
median. Differences between the groups were assessed using the Mann–Whitney U test. A p-value b0.05 was considered statistically signiﬁcant.
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cell subsets
Next to the ﬁrst line immune modulatory therapies, vitamin D has
been proposed to function as a natural immune modulator in RRMS.
Hence, we investigated the possible association between the vitamin
D status (serum 25(OH)D level) and the fractions of the different
cytokine producing Tc cell subsets in our cross-sectional cohort.
In HC and total RRMS patients in remission, serum 25(OH)D
levels were neither associated with Tc1 and Tc2 cell percentages
(r b 0.350 and p > 0.100 for all correlations) nor with Tc10 and
Tc17 cell percentages (r b 0.350 and p > 0.100 for all correlations,
Fig. 4A–D). Also, the double producing Tc cell percentages were not
associated with serum 25(OH)D levels neither in HC nor in total
RRMS patients in remission (r b 0.350 and p > 0.100 for all correla-
tions, data not shown). Next, we investigated if the vitamin D status
was associated with the Tc cell subsets within the different treatment
groups. Serum 25(OH)D levels were not associated with Tc1, Tc2,
Tc10, and Tc17 cells, or double producers in RRMS patients in remis-
sion without and with IFN-β treatment (r b 0.350 and p > 0.100 for
all correlations). In RRMS patients in remission with GA treatment,
serum 25(OH)D levels were positively correlated with the fractionTc10 cells (r = 0.597, p = 0.031), but not with the other Tc cell
fractions (r b 0.350 and p > 0.100 for all correlations).
Next, a possible add-on effect of vitamin D3 on the fraction of
cytokine expressing Tc cell subsets was assessed in 14 RRMS patients
in remission treated with IFN-β. These patients received daily
20,000 IU vitamin D3 for 12 weeks and the different Tc cell subsets
were determined at baseline and at 12 weeks. Percentages of Tc1,
Tc2, Tc10 and Tc17 cells were similar at baseline (17.5% [11.2–24.9],
0.8% [0.5–1.6], 0.2% [0.1–0.3] and 0.2% [0.1–0.3], respectively) and
after 12 weeks of vitamin D3 supplementation (18.1% [10.8–27.2],
0.9% [0.5–1.5], 0.2% [0.1–0.3] and 0.2% [0.2–0.3], respectively;
Fig. 4E–F). The double producing Tc cell frequencies at baseline did
not differ from these Tc cell frequencies 12 weeks after vitamin D3
supplementation (data not shown).
4. Discussion
In the present study, we show ﬁrst that Tc10 and Tc17 Tc cell
percentages are higher in untreated RRMS patients in remission
compared to HC. Second, percentages of the different Tc cell subsets
were similar between untreated RRMS patients in remission and
during a relapse. Third, IFN-β-treated RRMS patients in remission
Fig. 3. Treatment effects on the fraction cytokine producing CD8+ T cell subsets. The percentage of IFN-γ+ (A), IL-4+ (B), IL-10+ (C) and IL-17+ (D) cells within CD8+ T cells fromMS
patients in remission without (n = 16) or with beta interferon (IFN-β; n = 18) or glatiramer acetate therapy (GA; n = 13). Black horizontal lines indicate the median. Differences
between the groups were assessed using the Mann–Whitney U test. A p-value b0.05 was considered statistically signiﬁcant.
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cell percentages, compared to untreated RRMS patients in remission.
GA treatment did not affect any of the Tc cell subsets. Fourth, vitamin
D supplementation, as add-on to IFN-β therapy, did not inﬂuence
fractions of the different Tc cell subsets.
Tc cells are T cells with cytotoxic properties which are especially
important in controlling viral infections (reviewed by Zhang and
Bevan, 2011). Epstein–Barr virus (EBV), a risk factor for MS, might
be a pivotal link between Tc cells and MS (Ascherio and Munger,
2007). An in vitro study showed that Tc cells are able to induce
apoptosis in oligodendrocytes (Jurewicz et al., 1998). This could even-
tually result in a decreased myelinization of the axons and this might
add to MS pathogenesis. Next to the classical cytotoxic function, Tc
cells might exert helper functions through cytokine secretion, which
could play an important role in MS as well. In addition, cytotoxicity
and cytokine production can be produced in the same cell. Tc1 cells
seem to produce next to IFN-γ also perforin, while Tc17 cells seem
to be unable to produce this effector molecule. In MS, little research
has focused on cytokine producing Tc cell subsets and these studies
preferentially addressed Tc1 and Tc2 cells. Therefore, the main focus
of the present study was on Tc10 and Tc17 cell subsets, since these
subsets may have regulatory and pathogenic potential, respectively.
Our results show that untreated RRMS patients in remission had
an expanded Tc17 cell population compared to healthy controls,
while the percentage of this cell subset did not differ between
untreated RRMS patients in remission and during a relapse. Wang
et al. showed an elevated Tc17 cell fraction in MS patients during a
relapse compared to healthy controls, but did not include MS patients
in remission (Wang et al., 2011). In addition, a recent study showed
an increased Tc17 cell fraction in the CSF of clinically isolated
syndrome and early MS patients, but not in the periphery (Huberet al., 2013). The discrepancy between this and our study could be
explained by the differences in patient cohorts. Huber et al. included
patients during their ﬁrst clinical symptoms, while our patients were
in remission and would have, on average, a longer disease duration.
Moreover, their control cohort consisted of patients with non-infectious
headache, while we included HC. Tc17 cells can, like their T helper
counterpart (Th17 cells), be expected to play a pathogenic role in MS.
The observation that>70%of Tc cells inMS lesions express IL-17 supports
this. Moreover, recently Tc17 cells have been shown to be important in
the migration and accumulation of Th cells into the central nervous
system (CNS) and therefore seem essential in EAE induction (Huber
et al., 2013). To further investigate the role of these cells in the patho-
genesis, more functional studies should be performed. It would be
interesting to investigate the Tc17 cell responses to a probably more
representative antigen for MS, like myelin oligodendrocyte glyco-
protein or myelin basic protein.
Next to Tc17 cells, we observed an expanded Tc10 cell population
in untreated RRMS patients in remission. In contrast, Killestein et al.
observed a reduction in Tc10 cell percentages in RRMS patients
(Killestein et al., 2001). The discrepancy between the two studies
might be explained by the used patient materials (freshly isolated
PBMC in our study and thawed PBMC in Killestein's study). IL-10+ T
cell percentages might be more susceptible to differences in activa-
tion conditions, since we recently showed that monensin reduced
IL-10+ T cell percentages while it enhanced the other cytokine
producing T cell fractions (Muris et al., 2012). In linewith this, we spec-
ulate that Tc10 cell percentages can be affected by a freezing–thawing
cycle. Indeed, cytokine secretion or the fraction of cytokine positive
cells might differ between fresh and thawed PBMC (Mallone et al.,
2011). The results of the present study suggest that the immune system
tries to counterbalance the increase in pro-inﬂammatory cells by
Fig. 4. The effect of vitamin D on the fraction cytokine producing CD8+ T cell subsets. Correlations of serum 25(OH)D levels and either the percentage of IL-10+ (A, B) and IL-17+
(C, D) cells within CD8+ T cells from healthy controls (n = 30; A, C) and all RRMS patients in remission (n = 47; B, D). In B and D, black dots are RRMS patients in remission
without treatment (n = 16), black squares are RRMS patients in remission with beta-interferon (IFN-β, n = 18) treatment and open triangles are RRMS patients with glatiramer
acetate (GA, n = 13) treatment. The black lines are the best ﬁtted lines through the data points of HC (A, C) and all MS patients in remission (B, D). The percentage of IL-10+ (E) and
IL-17+ (F) cells within CD8+ T cells from MS patients in remission (n = 14) at baseline (before) and after 12 weeks (after) of 20,000 IU vitamin D3 per day. An association was
tested with the Spearman correlation. The correlation coefﬁcient and p-values are given. Differences between before and after were tested with a Wilcoxon Signed Ranks test.
A p-value b0.05 was considered statistically signiﬁcant.
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regulatory cells which are important in protection from tissue damage
during infections (reviewed by Zhang and Bevan, 2011). We speculate
that this function also exists during inﬂammation in autoimmune
diseases and that the expanded Tc10 cell population could protect
the brain tissue from damage in MS. This might be insufﬁcient during
disease exacerbation.
Th cells can express multiple cytokines simultaneously, even
cytokines which have been assigned to different Th cell subpopulations.
These double producing cells might exert distinct functions (Boniface
et al., 2010; Zielinski et al., 2012). Also, Th17 cells have been described
to be pathogenic cells in EAE, while Th cells producing both IL-17 and
IL-10 seem to be non-pathogenic (McGeachy et al., 2007). This might
also be true for Tc cells. Therefore, we assessed 3 different double
producing Tc cell subsets, i.e. IL-10+IL-17+, IFN-γ+IL-17+ and
IFN-γ+IL-10+ Tc cells. Our results showed that the frequency of the
ﬁrst is too low for reliable analysis, whereas the latter two Tc subsets
were elevated in untreated RRMS patients in remission. The low cellfrequencies of these double producing Tc cells implicate, however,
that the ﬁndings of these subsets in our cohort should be approached
with caution. Future studies investigating double producing Tc cells
should be more accurately designed for this purpose and if possible
elucidate the function of these cells.
GA and IFN-β are ﬁrst line immune modulatory drugs, which have
been shown to reduce the relapse rate (PRISMS, 1998; Comi et al.,
2001). Studies indicate that the induction of anti-inﬂammatory and
regulatory immune cells and the inhibition of pro-inﬂammatory
cells might contribute to the beneﬁcial effects of these therapies
(reviewed by Goodin, 2005; Lalive et al., 2011). In the present
study, we only observed a reduction in the Tc1 cell fraction in the
IFN-β-treated RRMS population. This is in agreement with previous
studies (Becher et al., 1999; Franciotta et al., 2003; Mei et al., 2006).
The Tc1 signature cytokine, IFN-γ, is involved in various immune
stimulating processes (Pouly et al., 2000). These observations suggest
a pathogenic role for this Tc cell subset and the observed reduction in
this subset might contribute to the clinical effect of IFN-β. The clinical
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numbers. However, a local effect of IFN-β or GA cannot be excluded. It is
possible that IFN-β and GA do not affect circulating Tc cell percentages,
but instead inﬂuence their function, e.g. cytokine secretion, prevent patho-
genic Tc cells fromentering the CNS or act locally on Tc cells, or act on other
pathogenic T cells.
Next to ﬁrst line medication, vitamin D is being advocated as a
possible add-on therapy because of its immune modulatory properties
(Smolders et al., 2010a, 2011). In autoimmune diseases, vitamin D
skews the immune system towards a more anti-inﬂammatory proﬁle
(reviewed by Peelen et al., 2011). Studies investigating the effects of
vitamin D on Tc cells are limited. Veldman et al. showed that Tc cells
express higher levels of the vitamin D receptor compared to Th cells
(Veldman et al., 2000). However, vitamin D has been shown to prevent
EAE independently of Tc cells (Meehan andDeLuca, 2002). Nonetheless,
vitamin D might have a beneﬁcial effect on Tc cells in MS patients.
Interestingly, Lysandropoulos et al. showed in vitro that vitamin D was
able to reduce IFN-γ and TNF-α secretion when Tc cells were
stimulated with either an EBV-peptide or anti-CD3 and anti-CD28 anti-
bodies (Lysandropoulos et al., 2011). Our data do not show an associa-
tion of the different Tc cell subsets and the vitamin D status in HC and
RRMS patients in remission. Recently, Stewart et al. showed that MS
patients with IFN-β treatment with a higher vitamin D status had a
reduced relapse rate (Stewart et al., 2012). This suggests a synergistic
effect of vitamin D and IFN-β treatment, which might also be true for
effects on the immune system. Therefore, we investigated the asso-
ciations in the different treatment groups. However, we did not observe
an association between the vitamin D status and the different Tc cell
subsets in RRMS patients in remission with IFN-β treatment nor in the
patients without treatment. Also, high dose vitamin D supplementation
in RRMS patients with IFN-β treatment did not affect these Tc cell
frequencies. In RRMS patients in remission with GA, we only observed
a positive association between the vitamin D status and Tc10 cell
percentages. Thismight indicate that vitaminD andGAhave a synergistic
effect on Tc10 cells.
This paper provides new insights in the frequency of circulating
Tc10 and Tc17 cells in RRMS patients in remission and during a
relapse. Furthermore, as far as we know, this is the ﬁrst paper that
assessed the effect of ﬁrst line treatment and vitamin D on Tc10 and
Tc17 cells in RRMS patients directly ex vivo. The present study has
some short comings. First, except for the vitamin D supplementation,
our study had a cross-sectional design, which gives no information on
causality. Second, we only assessed cells in the periphery and not
in CSF or brain tissue. Third, we investigated Tc cell percentages,
which do not give information on the amount of cytokines secreted
or other functional properties of these cells.
In conclusion, untreated RRMS patients in remission have an
augmented Tc10 and Tc17 cell fraction in the circulation, while during
a relapse the Tc cell subset percentages are similar to the percentages
of the patients in remission. Whether Tc10 and Tc17 cells are actively
involved in the pathogenesis of RRMS remains to be determined. If so,
new therapeutic modalities will be required since our data show that
current ﬁrst line medication does not affect the relative presence of
these Tc cell subsets.Acknowledgments
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